Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Employees

291

Sector

Biotechnology & Medical Research

Calendar

03-03 - Q4 2025 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Delayed Nasdaq Other stock markets 21:00:00 29/12/2025 GMT			5-day change	1st Jan Change
90.00 ^USD	-7.14%		-.--%	-

12-29	Merus N.V.(NasdaqGM:MRUS) dropped from NASDAQ Composite Index	CI
12-29	Genmab scraps development of experimental cancer therapy	RE

Capitalization	6.83B 5.81B 5.4B 5.06B 9.42B 625B 9.99B 61.6B 24.41B 295B 25.6B 25.07B 1,081B	P/E ratio 2026 *	-15.2x	P/E ratio 2027 *	-19.8x
Enterprise value	6.83B 5.81B 5.4B 5.06B 9.42B 625B 9.99B 61.6B 24.41B 295B 25.6B 25.07B 1,081B	EV / Sales 2026 *	2,275x	EV / Sales 2027 *	152x
Free-Float	97.53%	Yield 2026 *	-	Yield 2027 *	-

12-29	Merus N.V.(NasdaqGM:MRUS) dropped from NASDAQ Composite Index	CI
12-29	Genmab scraps development of experimental cancer therapy	RE
12-17	Merus N.V.(NasdaqGM:MRUS) dropped from S&P Global BMI Index	CI
12-12	Merus N.V. Appoints Van De Winkel as Chief Executive Officer, Effective December 12, 2025	CI
12-12	Merus N.V. Announces Board Changes	CI
12-12	Genmab Finalizes Tender Offer for Dutch Biotech Merus	MT
12-12	Genmab Completes Acquisition of Merus – Bolsters Portfolio with New Cancer Treatment	FW
12-12	Genmab: Completion of Tender Offer for Outstanding Common Shares of Merus N.V.	RE
12-10	Merus N.V.(NasdaqGM:MRUS) dropped from NASDAQ Biotechnology Index	CI
12-10	Genmab A/S completed the acquisition of Merus N.V. in a tender offer transaction.	CI
12-04	Genmab Closes $2.5 Billion Senior Notes Offering	MT
12-03	Genmab A/S and Genmab Finance LLC Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes	CI
11-19	Genmab Unit Prices $2.5 Billion Senior Notes Offering	MT

06/10/25	Leerink Partners Downgrades Merus to Market Perform From Outperform, Adjusts PT to $97 From $95	MT
30/09/25	Barclays Downgrades Merus to Equalweight From Overweight, Adjusts Price Target to $97 From $112	MT
30/09/25	Guggenheim Downgrades Merus to Neutral From Buy, Adjusts Price Target to $97 From $109	MT
30/09/25	BMO Capital Downgrades Merus to Market Perform From Outperform, Adjusts Price Target to $97 From $110	MT
29/09/25	HC Wainwright Downgrades Merus to Neutral From Buy, Price Target at $97	MT

Merus N.V. Share Price

Equities

MRUS

NL0011606264

Biotechnology & Medical Research

Valuation: Merus N.V.

Chart: Merus N.V.

Latest news: Merus N.V.

Last Transcript: Merus N.V.

Analysts' recommendations: Merus N.V.

Press Releases: Merus N.V.

News in other languages: Merus N.V.

Quotes and Performance

Course Extremes

Managers and Directors: Merus N.V.

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

12-16	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B	AQ
11-17	Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab	PR
11-12	Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights	PR
24/10/25	Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety	GL
23/10/25	Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS	BU

25/10/25	Tussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheid
24/10/25	HBM Healthcare confirme avoir redressé la barre à mi-parcours
14/10/25	Op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics kondigt Merus de publicatie aan van het abstract over petosemtamab in gemetastaseerde colorectale kanker
13/10/25	Merus kondigt de selectie aan van het abstract: Petosemtamab in Metastatic Colorectal Cancer (petosemtamab in gemetastaseerde colorectale kanker) voor mondelinge presentatie in de plenaire sessie op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
30/09/25	Nanobiotix, Genmab et Valneva grimpent, Asos déçoit

1 month	87.14	97
1 year	33.19	97.14
3 years	14.08	97.14
5 years	12.03	97.14
10 years	7.26	97.14

Manager	Title	Age	Since
Jan van de Winkel CEO	Chief Executive Officer	65	11/12/2025
Gregory Perry DFI	Director of Finance/CFO	65	13/06/2023
Fabian Zohren CTO	Chief Tech/Sci/R&D Officer	50	30/06/2024

Director	Title	Age	Since
Jan van de Winkel BRD	Director/Board Member	65	11/12/2025
Gregory David Emil Mueller BRD	Director/Board Member	54	11/12/2025
Anthony Pagano BRD	Director/Board Member	48	11/12/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MERUS N.V.	-7.14%	-.--%	+121.51%	+511.00%	6.83B
ARGENX SE	+1.00%	+1.85%	+14.19%	+94.60%	50.26B
WUXI APPTEC CO., LTD.	0.00%	-5.76%	+78.85%	+0.10%	41.75B
INSMED INCORPORATED	-3.26%	-3.14%	+100.86%	+633.69%	34.21B
BIONTECH SE	-0.69%	+8.43%	-3.22%	-17.77%	29.73B
WUXI BIOLOGICS (CAYMAN) INC.	+0.92%	-1.75%	+122.90%	-44.89%	20.65B
GENMAB A/S	+0.47%	-2.70%	+40.61%	-21.87%	20.51B
AKESO, INC.	+3.65%	-4.43%	+86.10%	+143.72%	13.28B
SUMMIT THERAPEUTICS INC.	+0.81%	+2.82%	-28.92%	+292.83%	13.39B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.07%	-8.67%	+169.00%	-	12.46B
Average	-0.08%	-1.54%	+70.19%	+176.82%	24.31B
Weighted average by Cap.	+0.03%	-0.60%	+59.34%	+146.79%

	2026 *	2027 *
Net sales	3M 2.55M 2.37M 2.22M 4.14M 275M 4.39M 27.07M 10.73M 130M 11.25M 11.02M 475M	45M 38.3M 35.57M 33.35M 62.1M 4.12B 65.84M 406M 161M 1.95B 169M 165M 7.12B
Net income	-462M -393M -365M -342M -638M -42.32B -676M -4.17B -1.65B -19.99B -1.73B -1.7B -73.15B	-435M -370M -344M -322M -600M -39.84B -636M -3.93B -1.56B -18.82B -1.63B -1.6B -68.87B
Net Debt	-	-

1 day	-7.14%
1 month	-7.17%
3 months	-4.66%
6 months	+42.27%